Bužga M et al., 2022-08-30: Narrative review of methylene blue toxicity concluding that its basic toxicology is unknown and that serious adverse effects can exceed the benefits for some indications. Directly relevant to the "safer than conventional painkillers" claim.
The toxic effects of the application of MB are dose-dependent and include serious symptoms such as hemolysis, methemoglobinemia, nausea and vomitus, chest pain, dyspnoea, and hypertension. Some countries regard MB as harmful because of the resulting skin irritation and triggering of an adverse inflammatory response. MB induced serotoninergic toxicity clinically manifests as neuromuscular hyperactivity.
Bužga M et al., 2022-08-30: Narrative review of methylene blue toxicity concluding that its basic toxicology is unknown and that serious adverse effects can exceed the benefits for some indications. Directly relevant to the "safer than conventional painkillers" claim. Study type: narrative review. N/A. Country: Czech Republic. MB by various routes; doses per reviewed reports. Funding/conflicts: not stated. Comparator: none. Lists hemolysis, methemoglobinemia, serotonin toxicity, skin and inflammatory reactions; states some countries regard MB as harmful because of skin irritation. Also filed as MTD-091, MTO-43 (claims C12, C16, C5). Study type: review.
